Full Press Release Details
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update.
ARGX
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
Key Takeaway: argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
Price reaction · baseline $464.36 (2024-07-24 close) · hit after-hours · clean, no other ARGX news in the window
day 0 close
+4.7%
day 1
+6.5%
day 3 · peak
+9.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis